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Abstract. 
 
We are interested in the signaling between 
axons and glia that leads to myelination and mainte-
nance of the myelin internode, and we have focused on 
the role of neuregulins and their receptors. Neuregulins 
are a family of ligands that includes heregulin, neu dif-
ferentiation factor, glial growth factor, and the acetyl-
choline receptor–inducing activity. Three signal trans-
ducing transmembrane receptors for neuregulins, 
which bear significant homology to the EGF receptor, 
are currently known: HER2 (erbB2), HER3 (erbB3), 
and HER4 (erbB4). We have found that oligodendro-
cite–type II astrocyte (O2A) progenitor cells and ma-
ture oligodendrocytes express HER2 and HER4 but no 
HER3. Schwann cells express HER2 and HER3 but lit-
tle HER4. In O2A progenitor cells and oligodendro-
cytes, recombinant neuregulin induces the rapid ty-
rosine phosphorylation of only HER4. HER2 is not 
phosphorylated in cells of the oligodendrocyte lineage, 
but a physical interaction between HER2 and HER4 
was detected in coimmunoprecipitation experiments. In 
Schwann cells, neuregulin induces the phosphorylation 
of both HER2 and HER3. Coimmunoprecipitation ex-
periments indicate that receptor activation in Schwann 
cells results in the formation of HER2:HER3 hetero-
dimers. Neuregulin localized immunocytochemically 
was present on neurites of cultured dorsal root ganglion 
neurons, and it was released into the medium in a form 
that promoted receptor tyrosine phosphorylation. Neu-
regulins therefore meet important criteria expected of 
molecules involved in axonal-glial signaling. The use of 
unique neuregulin receptor combinations in oligoden-
drocytes and Schwann cells likely results in recruitment 
of different signaling pathways and thus provides a ba-
sis for different biological responses.
 
B
 
ased
 
 on work of Richard and Mary Bunge, Patrick
Wood, and their colleagues, it was known for
some time that axons contain a mitogen(s) for
Schwann cells (5, 61, 62, 73). In 1978 a factor in pituitary
extracts was found to induce proliferation of Schwann
cells (58) and was named glial growth factor (GGF)
 
1
 
 (33).
GGF thus became a candidate for the axonal mitogen.
Amino acid sequence suggested that GGFs belonged to a
family of ligands now known collectively as neuregulins
(20, 39) and allowed cloning of full-length cDNAs (39).
Neuregulin has been used as a generic term for the homol-
ogous molecules heregulin, neu differentiation factor, ace-
tylcholine receptor–inducing activity, and GGF, and while
the term does not encompass the numerous biological ac-
tivities of this family of molecules outside the nervous sys-
tem, we will use it here for the sake of simplicity (15, 26,
39, 70). Recent experiments suggest that neuregulins are
responsible for part or all of the mitogenic effect of axons
on Schwann cells. Using the 2C4 antibody, which is an an-
tagonist for one of the neuregulin receptors, Bunge and
co-workers were able to block the mitogenic effect of dor-
sal root ganglion (DRG) neurons on Schwann cells (34, 46).
In related experiments, Jessen and colleagues found that
neuregulins induced survival of Schwann cell precursors
(11). Conditioned medium from DRG neurons possessed
a similar survival activity that was inhibited by a soluble
form of a neuregulin receptor that binds ligand and blocks
its ability to interact with native receptor (11).
The multiple isoforms of neuregulin originate from a
single gene (human chromosome 8p12-p21), probably by
use of multiple promoters and alternative mRNA splicing
(51). Most neuregulin isoforms encode a transmembrane
protein with a signal peptide–containing amino-terminal
domain, an immunoglobulin domain, an adjacent spacer
domain with 
 
N
 
- and 
 
O
 
-linked glycosylation sites, an EGF-
like domain with six conserved cysteines, a juxtamembrane
domain, a transmembrane domain, and a highly conserved
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Abbreviations used in this paper
 
: CNS and PNS, central and peripheral
nervous systems; DRG, dorsal root ganglion; E, embryonic day; EGFR,
epidermal growth factor receptor; GGF, glial growth factor; O2A, oligo-
dendrocyte–type II astrocyte; P, postnatal day; PVDF, polyvinyl difluo-
ride.
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cytoplasmic domain (4, 7, 52). Proteolytic cleavage of this
integral membrane form of neuregulin generates an extra-
cellular component of 
 
z
 
40–50 kD that has been referred
to as mature neuregulin (35, 71). The EGF-like domain
represents the minimal structure necessary for binding to
receptor and also for all known biological activities (8, 26).
Three disulfide bonds between cysteines 1 and 3, 2 and 4,
and 5 and 6 within the EGF-like domain are required for
activity and do so by bridging conserved amino acids at the
NH
 
2
 
-terminal and COOH-terminal ends of the EGF-like
domain suggested to play a role in specificity for its cog-
nate receptors (28).
Three transmembrane receptors for neuregulin are cur-
rently known—HER2/erbB2, HER3/erbB3, and HER4/
erbB4—all of which are homologous to the epidermal
growth factor receptor (EGFR), which is designated as
HER1/erbB1 (9, 31, 54). In common with other receptor
tyrosine kinases, ligand binding to HER receptors results
in activated receptor dimers. Of these receptors, HER3
and HER4, but not HER2 or HER1, directly bind neureg-
ulin with high affinity (8, 29, 53, 54). HER2 and HER4 have
functional intrinsic tyrosine kinases, whereas HER3 has
markedly reduced kinase activity (66). While HER2 lacks
the ability to bind soluble ligand directly, coexpression of
HER2 with HER3 significantly increases ligand affinity com-
pared with cells expressing HER3 alone (66). Many but
not all of the possible hetero- and homodimers—HER2:
HER3, HER2:HER4, HER3:HER4, HER4:HER4, and
EGFR:HER(2, 3 or 4)—become tyrosine phosphorylated
upon ligand binding and initiate signaling cascades (56,
66, 69).
In addition to their actions on Schwann cells, neuregu-
lins also act on oligodendrocytes, the myelin-forming cells
of the central nervous system (CNS), by inducing the ex-
tension of large sheetlike processes characteristic of a pre-
myelinating phenotype (68). In oligodendrocytes, neureg-
ulins induce the tyrosine phosphorylation of a 180–190-kD
protein. Neuregulins clearly have different effects on the
myelin-forming cells of the CNS and peripheral nervous
system (PNS), and we investigated if the signal transduc-
ing neuregulin receptors used by CNS and PNS glia dif-
fered. Neuregulin receptor usage will determine in part
the signaling pathways activated and thus the biological
response of a cell to neuregulins. In this report, we present
data showing oligodendrocyte–type II astrocyte (O2A)
progenitor cells and oligodendrocytes express the neureg-
ulin receptors HER2 and HER4, while Schwann cells ex-
press HER2 and HER3. Neuregulin induces the rapid
phosphorylation of HER4 in cells of the oligodendrocyte
lineage and both HER2 and HER3 in Schwann cells. We
determined that DRG neurons, which have both CNS and
PNS myelinated axons, express multiple neuregulin iso-
forms and demonstrate that neuregulin derived from
DRG neurons is biologically active.
 
Materials and Methods
 
Materials
 
The antigalactosylcerebroside monoclonal IgM, O1, was generated by Dr.
M. Schachner and colleagues, and the hybridoma was obtained from Dr.
Stephen Pfeiffer (University of Connecticut, Farmington, CT). Polyclonal
and monoclonal antibodies for HER2, HER3, HER4, and neuregulin
were obtained from Santa Cruz Laboratories (Santa Cruz, CA). An-
tiphosphotyrosine monoclonal antibody was G410.
 
Isolation of O2A Progenitor Cells
 
In the forebrain, oligodendrocytes arise in the subventricular zone (19)
from a bipolar cell that bears the surface marker A2B5, but not O4 or O1
(17). This cell is termed an oligodendrocyte–type II astrocyte (O2A) pro-
genitor cell because in vitro it has the potential to develop into an oligo-
dendrocyte or an astrocyte depending on culture conditions (59). In vivo
the O2A progenitor cell appears to develop predominantly along oligo-
dendrocyte lineage. O2A progenitor cells were isolated from the fore-
brains of 1-d-old Sprague Dawley rats using a previously described
method with slight modifications (68). After detachment of progenitors
from crude mixtures by a 15-h, 180-rpm shake, cells were exposed to leu-
cine methyl ester during three successive 15-min tissue culture plastic pan-
ning steps. This procedure reduced microglia to 
 
,
 
0.5% of the plating
mixture. Progenitors depleted of microglia were then plated onto polyorni-
thine-coated 22-mm glass coverslips or 60-mm tissue culture dishes in 5%
FCS and switched to defined medium for oligodendrocytes (DM
 
oli
 
) 30 min
after plating (day 0). DM
 
oli
 
 consisted of DME (GIBCO BRL, Grand Island,
NY), 0.5% recrystalized BSA, 5 
 
m
 
g/ml insulin, 100 
 
m
 
M putracine, 50 
 
m
 
g/ml
transferrin, 5 ng/ml selenium, 30 nM triiodothyronine, 20 nM progester-
one, and 10 ng/ml D-biotin (Sigma Chemical Co., St. Louis, MO).
 
Isolation of Schwann Cells
 
Schwann cells were isolated from postnatal day 0–1 (P0–P1) rat sciatic
nerves. Sciatic nerves were digested in 0.1% collagenase and 0.25% tryp-
sin and triturated with a 1-ml pipet ten times and then a fire-polished pas-
ture pipet seven times in 10% FBS. Dissociated cells from 40 sciatic
nerves were resuspended in 5 ml of DME with 10% FBS and plated into
a 25-cm
 
2
 
 flask. On the second day of culture, cells were treated with Ara-C
for 24 h to reduce fibroblast contamination. On day 4, cultures were
treated with GGF and forskolin (5 
 
m
 
M) to expand the Schwann cell popu-
lation. On day 7 in vitro, cultures were trypsinized, washed, and treated
with anti-Thy 1.1 followed by complement to eliminate remaining fibro-
blasts. Cells were plated onto polylysine-coated tissue culture dishes or
cover glasses for subsequent experiments.
 
Isolation of DRG Neurons
 
DRG neurons were isolated by digesting E15 rat DRGs in trypsin
(0.125% wt/vol) and collagenase (0.5% wt/vol) for 10–20 min, triturating
seven times with a fire-polished pasture pipet in 10% FBS, and then al-
lowing large undigested fragments to settle. Supernatants were collected
by centrifugation and pellets resuspended in DME with N2 additives, 2%
rat serum, and 50 ng/ml of NGF. Cells were plated onto polylysine- and
laminin-coated dishes and pulsed with 1 
 
m
 
M fluorodeoxyuridine and uri-
dine as described by (29a). Cultures usually required two to three fluoro-
deoxyuridine treatments to significantly reduce the numbers of Schwann
cells and fibroblasts.
 
Immunohistochemistry
 
Cultures of O2A progenitor cells, oligodendrocytes, Schwann cells, or
DRG neurons were fixed in fresh 4% paraformaldehyde in PBS (wt/vol)
for 7 min at ambient temperature, washed three times with PBS, perme-
abilized with 0.125% Triton X-100 in PBS (vol/vol) for 20 min at ambient
temperature, blocked with 5% nonfat dry milk in PBS (wt/vol) for 1 h, in-
cubated with primary antibody in blocking solution overnight at 4
 
8
 
C,
washed three times with PBS, and then incubated with Cy3-conjugated
secondary antibody (Jackson ImmunoResearch, West Grove, PA).
 
Immunoprecipitation
 
Cultures of O2A progenitor cells or oligodendrocytes in 60-mm tissue cul-
ture dishes were harvested on ice in lysis buffer (150 mM NaCl, 20 mM
Tris, 1 mM EDTA, 1.0% NP-40, 1 mM PMSF, 100 
 
m
 
g/ml leupeptin, 1 mM
sodium orthovanadate). Lysates were gently rotated at 4
 
8
 
C for 2 h and
cleared of insoluble material by precipitation at 10,000 
 
g
 
 for 5 min. Lysates
were then incubated 6–12 h with 1 
 
m
 
g/ml of primary antibody at 4
 
8
 
C with
gentle rotation. Antibody antigen complexes were precipitated after a 1-h
incubation with protein A–conjugated Sepharose 4B at 4
 
8
 
C with gentle ro-
tation. Immunoprecipitates were solubilized with loading buffer (10% SDS, 
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Tris, 
 
b
 
-mercaptoethanol, bromophenol blue), resolved on polyacrylamide
gels (5 or 4–15% gradient as indicated), and then transferred to polyvinyl
difluoride (PVDF) membranes (Millipore Corp., Bedford, MA).
 
Western Blotting
 
PVDF membranes with transferred protein were blocked with 3% nonfat
dry milk in PBS (wt/vol), pH 7.4, for 1 h at ambient temperature. Blocked
membranes were then incubated with primary antibody in PBS/milk for
2 h at ambient temperature, washed four times in PBS, incubated with the
appropriate peroxidase-conjugated secondary antibody for 1 h at ambient
temperature, and then washed four times for 15 min with PBS, and once
for 5 min with 0.05% Tween-20 in PBS (vol/vol). Washed blots were incu-
bated for 1 min with extended chemiluminescence reagents (New England
Nuclear, Boston, MA) and then exposed to x-ray film for the times indi-
cated.
 
Subcellular Fractionation
 
Subcellular fractions were prepared from 100-mm dishes of DRG neurons
plated at a density of 1 
 
3
 
 10
 
4
 
 cells/cm
 
2
 
 and that had been cultured 3 wk. Cul-
tures were washed with PBS, scraped in hypotonic buffer (20 mM Hepes,
pH 7.4, 10 mM KCl, 1.5 mM MgCl
 
2
 
, 1 mM PMSF), and lysed with 100 strokes
in a tight-fitting Dounce homogenizer. Nuclei and unlysed cells were pre-
cipitated by centrifugation at 1,500 
 
g
 
 for 5 min, and the pellet and superna-
tant were examined under a microscope to assure removal of nuclei and
unlysed cells. The supernatant from the 1,500 
 
g
 
 spin was then centrifuged
at 100,000 
 
g
 
 for 30 min, and the resulting supernatant was used as the cyto-
solic fraction and the pellet as the membrane fraction.
 
Conditioned Media
 
100-mm plates of DRG neurons 
 
z
 
3 wk in vitro and free of Schwann cells
were washed three times and switched to 5 ml of serum-free medium
(DME with N2 additives and 50 ng/ml of NGF) for 4 d. Conditioned me-
dia were collected and centrifuged at 1,000 
 
g
 
 to eliminate any precipitates
or cell fragments. Cleared media was then applied to an Amicon (Beverly,
MA) Centriprep concentrator with a 10-kD exclusion and used as de-
scribed by the manufacturer. The 5
 
3
 
 retentate was used in an assay of p185
tyrosine phosphorylation in L6 muscle cells as previously described (15).
 
Results
 
Oligodendrocytes Express Neuregulin Receptors HER2 
and HER4
 
Neuregulin receptor expression by O2A progenitor cells
and oligodendrocytes was evaluated by immunohistochem-
istry and Western blotting. O2A progenitor cells isolated
from P0 rat forebrain were grown in serum-free, chemi-
cally defined medium (see Materials and Methods) in the
presence of PDGF-AA and basic FGF to maintain cells as
a proliferating progenitor cell population (18, 41, 72), or in
the absence of these mitogens and in the presence of insu-
lin to allow for differentiation into oligodendrocytes. Both
O2A progenitor cells and oligodendrocytes stained with
antibodies directed against HER2 and HER4 (Fig. 1) but
not HER3 (not shown). The affinity of the HER3 anti-
body was adequate for immunohistochemistry as demon-
strated with Schwann cell staining (see Fig. 4). Specificity
of the HER2 and HER4 antibodies was shown by blocking
with an excess of peptide from which the antibodies were
raised (Fig. 1). 100% of O2A progenitor cells and oligo-
dendrocytes stain for HER2 or HER4 in single labeling
studies, and thus we infer that individual O2A progenitor
cells and oligodendrocytes possess both HER2 and HER4.
The staining pattern in O2A progenitor cells was similar but
not identical for HER2 and HER4. HER2 immunoreactiv-
ity was present throughout the entire length of the bipolar
processes in O2A progenitor cells, while HER4 immunore-
activity was absent in the distal-most ends of processes.
Western blot analysis confirmed the presence of signifi-
cant levels of HER2 and HER4 and the absence of HER3
in total lysates of cultured O2A progenitor cells and oligo-
Figure 1. HER2 and HER4 are present
on cells in the oligodendrocyte lineage.
O2A progenitor cells (upper) or oligo-
dendrocytes (lower) were fixed in fresh
4% paraformaldehyde and then perme-
abilized for 20 min in 0.125% Triton X-
100. These cultures were stained with
polyclonal antibodies that recognize in-
tracellular epitopes of the neuregulin
receptors and visualized using Cy3-con-
jugated secondary antibodies. Virtually
all cells were intensely labeled. Control
represents a culture of O2A progenitor
cells incubated with anti-HER4 in the
presence of 100-fold excess of the pep-
tide to which the antibody was raised
and similar results were obtained with
HER2. Bars, 50 mm. 
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dendrocytes (Fig. 2). In contrast to cells in the oligoden-
drocyte lineage, astrocytes express all three neuregulin
receptors (Fig. 2). Unlike cells in the oligodendrocyte lin-
eage, Schwann cells express large amounts of HER3 (Fig.
2). Schwann cells also express quantitatively more HER2
than do cells in the oligodendrocyte lineage. Schwann cells
express only trace amounts of HER4 (Fig. 2). Similar ex-
periments in both mouse and rat have shown expression of
HER2 and HER3 by Schwann cells (24, 34, 45, 46).
 
Neuregulin Induces the Tyrosine Phosphorylation
of HER4 but Not HER2 in O2A Progenitor Cells
and Oligodendrocytes
 
Cells of the oligodendrocyte lineage express HER2 and
HER4, and therefore HER2:HER2, HER4:HER4, and
HER2:HER4 homo- and heterodimers are possible signal
transducing receptor units. In transfected cell lines, data
suggest that HER2:HER2 homodimers are not functional
signal transducing units because they lack the ability to
bind neuregulin. To investigate receptor usage in primary
glial cells, we examined O2A progenitor cells and oligo-
dendrocytes for the receptor tyrosine phosphorylation events
after treatment with neuregulin. In the upper panel of Fig.
3 
 
A
 
, the tyrosine phosphorylation of an 
 
z
 
180-kD protein
is evident in HER4 and HER2 immunoprecipitates from
both neuregulin-treated O2A progenitor cells and oligo-
dendrocytes. HER2 and HER4 may be resolved by SDS-
PAGE with approximate molecular masses of 185 and 180
kD, respectively, and based on relative mobility of the two
receptors, it appeared that the tyrosine-phosphorylated
protein was HER4 rather than HER2. To definitively as-
sign the tyrosine-phosphorylated protein to either HER2 or
HER4, we stripped the membranes and reprobed them for
either HER2 (Fig. 3 
 
A
 
, 
 
middle
 
) or HER4 (Fig. 3 
 
A
 
, 
 
lower
 
).
Based on alignment of the resultant autoradiograms, it
was clear that the tyrosine-phosphorylated band comi-
grated with HER4 and not HER2. Significant amounts of
HER4 were present in HER2 immunoprecipitates in both
ligand-treated and control cultures, but little HER2 was
detected in HER4 immunoprecipitates. This suggested to
us that HER2:HER4 heterodimers may exist in the pres-
Figure 2. Distinct neuregulin receptor expression by CNS and
PNS glial cells. Primary cultures of astrocytes, O2A progenitor cells,
oligodendrocytes, and Schwann cells were prepared as described.
Cell lysates containing 10 mg of protein were resolved on 4–15%
gradient polyacrylamide gels and probed with HER2, HER3, or
HER4 antibodies. Cells in the oligodendrocyte lineage express
HER2 and HER4, Schwann cells express HER2 and HER3, and
astrocytes express HER2, HER3, and HER4.
Figure 3. Neuregulin-induced tyrosine phosphorylation of HER4
in O2A progenitor cells and oligodendrocytes. (A) Cultures were
treated with 100 pM neuregulin (EGF-like b1 domain of neu dif-
ferentiation factor) or control buffer (0.1% recrystalized BSA in
PBS) for 5 min, harvested, and HER4 or HER2 immunoprecipi-
tated as described. All three panels represent autoradiographs of
the same membrane probed sequentially with three different
primary antibodies: monoclonal antiphosphotyrosine (upper),
polyclonal anti-HER2 (middle), and anti-HER4 (lower). Before
reprobing the membrane, primary and secondary antibody com-
plexes were stripped as described in Materials and Methods. In
both O2A progenitor cells and oligodendrocytes, neuregulin in-
duces the phosphorylation of a band at z180-kD that comigrates
with HER4 but not HER2. HER4 is seen in the HER2 immuno-
precipitates regardless of neuregulin treatment, indicating an as-
sociation of the two receptors in the absence of ligand. The bands
at z190 and 135 kD recognized by HER4 antibodies in HER4
immunoprecipitates (lower) are of unknown significance but may
represent unprocessed and truncated forms of the receptor. (B)
Time course of HER4 phosphorylation. Cultures of O2A progen-
itors were treated for the times indicated and HER4 was immu-
noprecipitated. Immunoprecipitates were treated as above using
monoclonal antiphosphotyrosine as the primary antibody, and
the autoradiograph is shown. 
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ence and absence of ligand. Furthermore, the fact that
HER4 is present in HER2 immunoprecipitates but not the
converse suggests that HER4 is in excess of HER2 and
that HER4 homodimers actually form. The definitive
demonstration of HER4 homodimers will require chemi-
cal cross-linking studies.
HER4 is phosphorylated rapidly in cells of the oligoden-
drocyte lineage. In the experiment shown in Fig. 3 
 
B
 
, O2A
progenitor cells were treated for the times indicated with
neuregulin, and HER4 was immunoprecipitated. Tyrosine
phosphorylation of HER4 in O2A progenitor cells was de-
tectable 60 s after exposure to neuregulin and persisted for
 
.
 
1 h (Fig. 3 
 
B
 
).
 
Schwann Cells Express Neuregulin Receptors HER2 
and HER3
 
In contrast to cells of the oligodendrocyte lineage, neureg-
ulins induce a mitogenic response in Schwann cells (20, 39,
46, 68). We sought to determine if the different biological
responses of CNS and PNS myelin-forming cells to neu-
regulins could be accounted for by different neuregulin re-
ceptors used by each cell type. In contrast to oligodendro-
cytes and O2A progenitor cells, cultured Schwann cells
labeled intensely for HER3 as well as HER2 (Fig. 4). The
labeling pattern for both receptors was the same, staining
processes and the cell body equivalently.
 
Neuregulin Induces the Tyrosine Phosphorylation of 
HER2 and HER3 in Schwann Cells
 
We examined total lysates of Schwann cells and found that
neuregulin induced the rapid tyrosine phosphorylation of
a 170–190-kD protein detected 1 min after treatment, peak-
ing in intensity at 30 min (Fig. 5). At the time of peak tyro-
sine phosphorylation, a mobility shift in the HER2 band
was observed (Fig. 5). This suggests that the change in elec-
trophoretic properties results from the increased phosphor-
ylation, as has been noted with other proteins (27). After
more prolonged treatment, the HER2 band migrated to its
pretreatment mobility. Furthermore, the amount of HER2
in these total lysates had apparently decreased at later
time points, perhaps reflecting ligand-dependent degrada-
Figure 4. HER2 and HER3 are present on Schwann cells. Schwann cells were cultured as described, fixed in 4% paraformaldehyde,
permeabilized with 0.125% Triton X-100, and stained with polyclonal antisera directed against HER2 or HER3 followed by Cy3-conju-
gated secondary antibodies. Virtually all Schwann cells stain for both HER2 and HER3. Bar, 50 mm.
Figure 5. Neuregulin induces a mobility shift in HER2 and HER3
and the rapid phosphorylation of a 180–190-kD protein in
Schwann cells. Schwann cells were cultured as described in Mate-
rials and Methods, treated with neuregulin for the times indicated
(control, 10 s, 1 min, 30 min, 1 h, 6 h, 12 h, and 24 h), and then lysed
with ice-cold lysis buffer. Total cell lysates were resolved by 5%
PAGE and transferred to PVDF membranes. HER2 and HER3
were visualized with polyclonal antisera, and tyrosine-phosphory-
lated proteins were visualized with the monoclonal antibody G410. 
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tion (Fig. 5). Neuregulin also stimulates a mobility shift in
the HER3 immunoreactive band over the same time
course (Fig. 5). Unlike HER2 however, the intensity and
mobility of the HER3 band is sustained for 
 
.
 
12 h.
Activation of neuregulin receptors in Schwann cells was
studied in further detail by immunoprecipitation of neu-
regulin receptors followed by blotting with antiphosphoty-
rosine antibodies. Recent studies in which total tyrosine-
phosphorylated proteins were immunoprecipitated from
Schwann cells treated with neuregulin demonstrated the
phosphorylation of HER2 and HER3 (24). However, such
an analysis precludes investigating receptor heterodimer-
ization. In the experiments described below, Schwann cells
were treated for 20 min with neuregulin or control buffer
(PBS), and individual neuregulin receptors were immu-
noprecipitated as described in the Materials and Methods.
Neuregulin induces the tyrosine phosphorylation of a 180–
190-kD band detected in both HER2 and HER3 immuno-
precipitates (Fig. 6 
 
A
 
). We again identified a neuregulin
induced mobility shift of 
 
z
 
5 kD that occurs upon phos-
phorylation for HER2. Two antibodies were used to ex-
amine HER3 on Western blots: a monoclonal antibody
that has not been mapped to a specific domain of the re-
ceptor and a polyclonal antibody that was raised against a
peptide in the COOH terminus of HER3 that contains a
consensus sequence for tyrosine phosphorylation. When
blots were stripped and reprobed using the HER3 mono-
clonal antibody, a similar mobility shift was observed as
broadening of the HER3 band (Fig. 6 
 
A
 
). This mobility
shift was not observed with the HER3 polyclonal antibody
because this antibody does not recognize the phosphory-
lated form of HER3 as well as dephospho-HER3 on West-
ern blots (Fig. 6 
 
A
 
).
Prolonged exposure of the above blots shows HER3 im-
munoreactivity in HER2 immunoprecipitates and HER2
immunoreactivity in HER3 immunoprecipitates from neu-
regulin-treated but not control Schwann cells (Fig. 6 
 
B
 
).
This indicates that neuregulin induces receptor hetero-
dimerization in Schwann cells. We cannot rule out the ex-
istence of receptor homodimers as well.
Figure 6. Neuregulin induces the tyrosine
phosphorylation of HER2 and HER3, and
the formation of HER2:HER3 hetero-
dimers. Schwann cells were treated with a
control solution (PBS) or 100 pM neureg-
ulin for 20 min and then lysed in ice-cold
lysis buffer. HER2, HER3, and HER4
were immunoprecipitated from lysates as
previously described. Immunoprecipitates
were resolved by 5% SDS-PAGE, pro-
teins were transferred to PVDF mem-
branes, and membranes were probed with
the indicated antibodies. 
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Sensory Neurons Express Multiple Neuregulins That 
Are Biologically Active
 
Having established that CNS and PNS glia have distinct
neuregulin receptors, we wanted to determine if neurons
secreted neuregulins and if they were present on the cell
surface. We chose DRG neurons to study because they
possess both CNS and PNS myelinated axons. Sensory neu-
rons were obtained from the dorsal root ganglia of em-
bryonic day (E)15 rats and were freed of fibroblasts and
Schwann cells by treatment with 5-fluorodeoxyuridine as
described in the Materials and Methods section. Neuregu-
lin staining, detected with an antibody recognizing a COOH
terminus cytoplasmic domain, is present in both the soma
and neurites of cultured DRG neurons (Fig. 7 
 
A
 
). Cul-
tured sensory neurons express three forms of membrane-
associated neuregulin by Western blot analysis with appar-
ent molecular masses of 144, 84, and 55 kD (Fig. 7 
 
B
 
). The
84-kD band is consistent with a full-length Ig-domain–con-
taining protein. A neuregulin isoform of 
 
z
 
144 kD was pre-
viously noted in Western blots of rat spinal cord (63). An
 
z
 
144-kD isoform can be predicted from known alterna-
tive splice sites, but such a cDNA has not been cloned. A
55-kD band was present in both membrane and cytosolic
fractions. The 55-kD band in membrane fractions likely
Figure 7. DRG neurons express multiple neuregulin isoforms. (A) Neurons isolated from E15 DRGs were cultured for 3 wk as de-
scribed, fixed, and stained with an antibody that recognizes a peptide within the COOH terminus of the neuregulin “a” form. Immu-
noreactive cells were recognized with Cy3-conjugated secondary antibodies and epifluorescence. Both processes and soma stain in-
tensely for neuregulin. (B) Western blot of cytosolic and membrane fractions from DRG neurons. Neurons isolated from DRGs were
cultured for 3 wk and lysed in hypotonic buffer, and membrane and cytosolic fractions were prepared as detailed in Materials and Meth-
ods. Proteins were solubilized in SDS-DTT–containing buffer and resolved on 4–15% gradient gels, and the resulting blots were probed
with the antineuregulin antibody described above. Bar, 50 mm. 
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represents the remaining transmembrane domain plus the
cytosolic domain after extracellular proteolytic processing
of full-length neuregulin. In the cytosol, this 55-kD band is
the free soluble cytosolic domain, which has not been pre-
viously demonstrated as a stable product of neuregulin
processing (Fig. 7 
 
B
 
). These results suggests that, in addi-
tion to cell surface neuregulins, a proportion of the neu-
regulins expressed by sensory neurons are processed to re-
lease the extracellular domain.
Both neuregulin secreted into the medium and that as-
sociated with the cell surface possess biological activity.
Concentrated conditioned medium and a preparation of
cell membranes from sensory neuron cultures were tested
for p185 (neuregulin receptor) tyrosine phosphorylation
using L6 muscle cells, which express high levels of neureg-
ulin receptors. The conditioned medium samples stimu-
lated significant p185 phosphorylation, confirming that ac-
tive neuregulins are released by sensory neurons in culture
(Fig. 8). Furthermore, the DRG cell membranes were also
positive in this assay, demonstrating that surface bound
neuregulins are able to play a role in signaling (Fig. 8).
 
Discussion
 
Our data provide evidence for unique neuregulin receptor
usage in glial cells. Neuregulin signaling in Schwann cells is
different from that in O2A and oligodendrocyte cells in a
number of respects. HER2 and HER3 are the major re-
ceptors on Schwann cells, in agreement with previous
reports (24, 34, 45, 46), whereas HER2 and HER4 pre-
dominate in oligodendroglial cells. In Schwann cells, no
heterodimers were detected in the absence of ligand,
whereas in oligodendroglial cells, HER2:HER4 hetero-
dimers were identified. Addition of neuregulins to Schwann
cells induced HER2:HER3 heterodimerization and tyro-
sine phosphorylation of both subunits.
In oligodendroglial cells, no ligand-dependent change in
the amount of HER heterodimers was observed, and only
HER4 was tyrosine phosphorylated. Although this might
suggest that neuregulins signal primarily through HER4
homodimers in cells of the oligodendrocyte lineage, we
clearly detected ligand-dependent activation of HER4 in
HER2:HER4 heterodimers, suggesting these hetero-
dimers also play a role. The levels of one receptor subunit,
HER2, decline in Schwann cells after prolonged exposure
to ligand. If the biological outcome in response to neureg-
ulins is due to neuregulin receptor usage, then the phos-
phorylation of HER2 and/or HER3 may be relevant to a
mitogenic response in Schwann cells, and the absence of
these phosphorylation events may explain the absence of a
mitogenic response in cells of the oligodendrocyte lineage.
The presence of phosphorylated HER4 may play a role in
signaling differentiation when it is the dominant neuregu-
lin receptor expressed and phosphorylated, as in oligoden-
drocytes. In addition to differences in neuregulin receptor
isotypes between PNS and CNS glia, Schwann cells also
express quantitatively more receptor than do CNS glia.
Thus, it is possible that the differences in biological effects
of neuregulins on Schwann cells and cells in the oligoden-
drocyte lineage are due to receptor number as well as iso-
type. While we did not study neuregulin receptor phos-
phorylation in astrocytes, we did determine that astrocytes
express HER2, HER3, and HER4. Neuregulin acts as a sur-
vival factor for astrocytes, and it will be interesting to de-
termine if this survival effect is imparted by unique neu-
regulin receptor usage. The absence of detectable HER3
in our cultures of O2A progenitor cells and oligodendro-
cytes argues for minimal astrocytic contamination of these
cells.
The cellular response of Schwann cells to neuregulins
differs depending on the stage of development. Neuregu-
lins restrict neural crest cells to a glial fate at E10.5 (65), pro-
mote the survival of Schwann cell precursors at E15–16
(11), and stimulate proliferation of mature Schwann cells
at P0–1 (11, 34, 39, 46). Given the apparent dependence of
neuregulin responses upon relative HER receptor subunit
levels, it will be interesting to compare receptor expression
at these different stages and additionally later on during
myelination of peripheral nerve.
The task of myelination is accomplished by oligoden-
drocytes in the CNS and by Schwann cells in the PNS. The
intimate relationship between axon and oligodendrocyte
or Schwann cell that culminates in formation of the myelin
internode is predicted to require specific receptor-medi-
ated events and subsequent intracellular signaling from
axon to myelin-forming cell and from myelin-forming cell
to axon. The known or inferred signal transducing surface
receptors on O2A progenitor cells and oligodendrocytes
include the PDGF receptor, FGF receptor, CNTF/LIF re-
ceptors, IGF-I receptor, and the retinoic acid receptor (1–3,
14, 16–18, 21, 22, 23, 25, 37, 40, 42–44, 50, 60) in addition to
specific glycolipids present on the oligodendrocyte surface
Figure 8. Neuregulin from DRG neurons is biologically active.
Conditioned medium isolated from two separate cultures of DRG
neurons (DRG CM 1 and 2) and membrane vesicles from DRG
neurons were prepared as described and studied for their ability
to induce tyrosine phosphorylation of p185 in L6 cells. L6 cells
were incubated with conditioned medium for 30 min and then
harvested in SDS-loading buffer with b-mercaptoethanol. Ly-
sates were resolved on 5% polyacrylamide gels, and proteins
were transferred to PVDF membranes that were probed with an-
tiphosphotyrosine antibodies. p185 phosphorylation is evident in
L6 cells treated with DRG-conditioned medium, EGFb1-like do-
main of neu differentiation factor, and recombinant acetylcholine
receptor–inducing activity, but not control medium or fibroblast
conditioned medium. 
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thought to play a role in transducing signals (12, 13). How-
ever, of these receptors, none have ligands that are known
to be expressed on the surface of axons (10, 30, 38, 47–49,
57, 64, 67).
To support the idea that axonal-derived neuregulin acts
as a ligand for neuregulin receptors on O2A progenitor
cells and Schwann cells, we examined DRG neurons for
production of neuregulins. Myelinated axons of DRG neu-
rons exist in peripheral nerve and the dorsal columns in the
CNS. Thus, DRG neurons are a reasonable cell to study
for axonal-derived factors that may influence both
Schwann cells and oligodendrocytes. In conditioned me-
dium from DRG neurons, there is neuregulin activity as
determined by assay of receptor phosphorylation, support-
ing the concept that soluble ligand is released from neurons.
Membrane fractions of DRG neurons are also capable of
stimulating receptor phosphorylation, and thus we argue
that membrane-associated neuregulin is also capable of
activating receptors. There are three membrane-associ-
ated forms of neuregulin in DRG neurons that we detected
with antibodies recognizing a COOH-terminal epitope re-
stricted to the “a”-cytoplasmic domain (71). Two of these
membrane-associated forms (100 and 140 kD) represent
large transmembrane forms of neuregulin, and the smaller
50-kD membrane-associated form is most likely the intact
cytosolic and transmembrane domains minus the extracel-
lular domain. The released, soluble cytosolic domain is
clearly present and stable in cytosolic fractions. These data
suggest that there may be two processing events for trans-
membrane forms of neuregulin occurring at the extracellu-
lar surface to release ligand into the extracellular spaces,
and at the intracellular surface to release the cytosolic do-
main into the cytosol. The function of the cytosolic domain
is unknown, but its importance is implied by being the
most conserved domain between different neuregulins.
In our cultures, O2A progenitor cells and oligodendro-
cyte cells are indistinguishable, both in terms of HER recep-
tors expressed and in terms of the tyrosine phosphorylation
response to added neuregulin, suggesting that maturation
of this lineage does not alter neuregulin responsiveness. It
is interesting to note that O2A progenitor cells that have
been expanded six passages in conditioned medium from
the B104 cell line (6), akin to conditions used to generate
the CG4 glial cell line (36), express HER3 abundantly and
have relatively less HER4 (6). The cellular response to neu-
regulins in these cells is dramatically different to that of
primary O2A progenitor cells or oligodendrocyte cells;
neuregulins stimulate a robust mitogenic response and ar-
rest differentiation into mature oligodendrocytes (6). We
speculate that the expression of high levels of HER3 is re-
sponsible for these changes. However, it is possible that
other changes in cell cycle control occur with manifold
passaging of primary glial cells (32, 55). Future experiments
to prove the premise that HER3 specifies a mitogenic sig-
nal will involve transfecting cells of the oligodendrocyte
lineage with HER3 expression vectors.
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